|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2003-4-2
|
|
pubmed:abstractText |
To evaluate the significance of pretreatment prostate-specific antigen (pPSA) levels as a predictor of overall survival simultaneously with previously established prognostic factors. The pPSA level is a major predictor of treatment failure after radiotherapy and surgery, but to date has not been shown to predict survival.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1527-9995
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
61
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
730-5
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12670556-Adenocarcinoma,
pubmed-meshheading:12670556-Aged,
pubmed-meshheading:12670556-Disease-Free Survival,
pubmed-meshheading:12670556-Humans,
pubmed-meshheading:12670556-Male,
pubmed-meshheading:12670556-Multivariate Analysis,
pubmed-meshheading:12670556-Prognosis,
pubmed-meshheading:12670556-Prostate-Specific Antigen,
pubmed-meshheading:12670556-Prostatic Neoplasms,
pubmed-meshheading:12670556-Radiotherapy, Conformal,
pubmed-meshheading:12670556-Survival Analysis,
pubmed-meshheading:12670556-Treatment Failure
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Serum prostate-specific antigen and survival after external beam radiotherapy for carcinoma of the prostate.
|
|
pubmed:affiliation |
Department of Radiation Oncology, University of California, San Francisco, School of Medicine, 94143-1708, USA.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
